Vir Biotechnology Inc (VIR) - Total Assets
Based on the latest financial reports, Vir Biotechnology Inc (VIR) holds total assets worth $1.03 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Vir Biotechnology Inc to assess how comfortably operating cash covers total debt obligations.
Vir Biotechnology Inc - Total Assets Trend (2017–2025)
This chart illustrates how Vir Biotechnology Inc's total assets have evolved over time, based on quarterly financial data. See VIR book value for net asset value and shareholders' equity analysis.
Vir Biotechnology Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Vir Biotechnology Inc's total assets of $1.03 Billion consist of 51.3% current assets and 48.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.3% |
| Accounts Receivable | $3.60 Million | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.85 Million | 0.8% |
| Goodwill | $16.94 Million | 1.7% |
Asset Composition Trend (2017–2025)
This chart illustrates how Vir Biotechnology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VIR market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vir Biotechnology Inc's current assets represent 51.3% of total assets in 2025, a decrease from 76.5% in 2017.
- Cash Position: Cash and equivalents constituted 23.3% of total assets in 2025, down from 74.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 20.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 1.7% of total assets.
Vir Biotechnology Inc Competitors by Total Assets
Key competitors of Vir Biotechnology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Genfit S.A.
PA:GNFT
|
France | €157.93 Million |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
Altimmune Inc
NASDAQ:ALT
|
USA | $279.93 Million |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$255.67 Million |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
China | CN¥1.48 Billion |
Vir Biotechnology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.11 | 6.79 | 5.91 |
| Quick Ratio | 7.11 | 6.79 | 5.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $449.43 Million | $794.92 Million | $716.27 Million |
Vir Biotechnology Inc - Advanced Valuation Insights
This section examines the relationship between Vir Biotechnology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.75 |
| Latest Market Cap to Assets Ratio | 1.43 |
| Asset Growth Rate (YoY) | -28.3% |
| Total Assets | $1.00 Billion |
| Market Capitalization | $1.44 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Vir Biotechnology Inc's assets above their book value (1.43x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Vir Biotechnology Inc's assets decreased by 28.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vir Biotechnology Inc (2017–2025)
The table below shows the annual total assets of Vir Biotechnology Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.00 Billion | -28.31% |
| 2024-12-31 | $1.40 Billion | -27.11% |
| 2023-12-31 | $1.92 Billion | -31.51% |
| 2022-12-31 | $2.80 Billion | +43.38% |
| 2021-12-31 | $1.95 Billion | +112.71% |
| 2020-12-31 | $918.76 Million | +79.42% |
| 2019-12-31 | $512.07 Million | +167.27% |
| 2018-12-31 | $191.60 Million | -23.84% |
| 2017-12-31 | $251.57 Million | -- |
About Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those ta… Read more